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This pragmatic randomized controlled trial tested the effectiveness of long-term psychoanalytic psychotherapy (LTPP) as an adjunct to treatment-
as-usual according to UK national guidelines (TAU), compared to TAU alone, in patients with long-standing major depression who had failed at
least two different treatments and were considered to have treatment-resistant depression. Patients (N5129) were recruited from primary care and
randomly allocated to the two treatment conditions. They were assessed at 6-monthly intervals during the 18 months of treatment and at 24, 30
and 42 months during follow-up. The primary outcome measure was the 17-item version of the Hamilton Depression Rating Scale (HDRS-17),
with complete remission defined as a HDRS-17 score 8, and partial remission defined as a HDRS-17 score 12. Secondary outcome measures
included self-reported depression as assessed by the Beck Depression Inventory - II, social functioning as evaluated by the Global Assessment of
Functioning, subjective wellbeing as rated by the Clinical Outcomes in Routine Evaluation - Outcome Measure, and satisfaction with general
activities as assessed by the Quality of Life Enjoyment and Satisfaction Questionnaire. Complete remission was infrequent in both groups at the
end of treatment (9.4% in the LTPP group vs. 6.5% in the control group) as well as at 42-month follow-up (14.9% vs. 4.4%). Partial remission was
not significantly more likely in the LTPP than in the control group at the end of treatment (32.1% vs. 23.9%, p50.37), but significant differences
emerged during follow-up (24 months: 38.8% vs. 19.2%, p50.03; 30 months: 34.7% vs. 12.2%, p50.008; 42 months: 30.0% vs. 4.4%, p50.001).
Both observer-based and self-reported depression scores showed steeper declines in the LTPP group, alongside greater improvements on measures
of social adjustment. These data suggest that LTPP can be useful in improving the long-term outcome of treatment-resistant depression. End-of-
treatment evaluations or short follow-ups may miss the emergence of delayed therapeutic benefit.
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The potential to follow a chronic, relapsing course is a
substantial part of what makes depression one of the largest
contributors to the burden of human disease worldwide
(1,2). Treatments for major depressive disorder generally
have medium effect sizes (3), but observational studies and
trials consistently report high rates of non-response (4,5),
with 12 to 20% of depressed patients not benefitting even
from multiple courses of treatment (6). This is often termed
treatment-resistant depression.
Recent systematic reviews of treatment research for this
patient group, whether considered separately (7) or combined
with chronic major depressive disorder (8), revealed that
existing studies are mostly of poor quality and design (9). Tri-
als of novel neuromodulation therapies – such as repetitive
transcranial magnetic stimulation (10), deep brain stimulation
(11) and vagus nerve stimulation (12) – with these patients
have shown serious limitations. There is some evidence sup-
porting the augmentation of initial antidepressant medication
with other classes of drugs (e.g., atypical antipsychotics) (7),
or the adjunct of cognitive-behavioral therapy (CBT) to that
medication (8,13), at least for patients with severe but non-
chronic (episode2 years) major depression (14).
Evidence is accumulating that, in order to be effective,
interventions for treatment-resistant depression may need
to be longer and more complex than first-line treatments of
depression (15), and that follow-ups should be longer (16).
Some empirical evidence for short-term psychodynamic
psychotherapies in the treatment of depression is available
(e.g., 17). However, given the likelihood that a longer inter-
vention will be needed, these therapies may have little rele-
vance to populations of patients with treatment-resistant
depression (18).
Evidence-gathering regarding the effectiveness of longer-
term, more intensive psychoanalytic treatments is in its early
stages (19). One recent meta-analysis identified 27 studies,
most being either observational or quasi-randomized, with
groups matched retrospectively (20). One quasi-randomized
but otherwise methodologically strong study found long-
term psychodynamic psychotherapy to be less effective over
the short term than brief focused therapies for a sample of
mood-disordered patients. However, after a 3-year follow-
up, long-term psychodynamic psychotherapy was found to
be superior (21).
Notwithstanding their various methodological shortcom-
ings, the findings of studies with a multi-year follow-up period
do suggest that there may be benefits from long-term psycho-
dynamic psychotherapy (50 sessions) for patients with
depression (20,22), particularly in the longer term (18,23).
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Given the limitations of the evidence base concerning
management of treatment-resistant depression, the present
pragmatic randomized controlled trial assessed whether this
condition is more likely to improve when long-term psycho-
analytic psychotherapy (LTPP) is provided in addition to
treatment-as-usual according to UK national guidelines
(TAU), but excluding the short-term forms of psychological
therapy recommended by those guidelines. We hypothesized,
on the basis of accumulating evidence from non-randomized
controlled studies (20-22), that the effect of LTPP would
increase over the course of a longer than usual follow-up
period.
METHODS
Study design and participants
Patients were recruited from primary care from February
2002 to May 2009 and assessed at the Adult Service of the
Tavistock & Portman National Health Service (NHS)
Foundation Trust in London. They were not paid and con-
sented only after receiving a complete written description
and thorough discussion of the study.
After baseline assessment, randomization to an 18-month
course of LTPP plus TAU or TAU alone was carried out off-
site by an independent statistician using a stochastic minimi-
zation program (MINIM) balancing for gender, depression
severity (scores of 21-39 or 401 on the Beck Depression
Inventory - II, BDI-II (24)), and medication (on/off). Pa-
tients were then followed up for 24 to 42 months post-
randomization according to an intention-to-treat design.
The trial methodology was published in advance of trial
completion and data analysis (25). The study protocol was
registered with the International Randomized Controlled
Trial Number Register (ISRCTN40586372), and approved
by the Institutional Review Board of NHS West Midlands
Research Ethics Committee (MREC02/07/035).
In total, 308 patients were screened for eligibility. Of
these, 235 attended for interview. Inclusion criteria were:
age 18-65 years; current DSM-IV diagnosis of major depres-
sive disorder as ascertained by the Structured Clinical Inter-
view for DSM-IV (SCID-I, 26); minimum duration of two
years of the current depressive episode; minimum score of
14 on the 17-item version of the Hamilton Depression Rat-
ing Scale (HDRS-17, 27) and of 21 on the BDI-II; and at
least two failed treatment attempts (elicited at interview and
verified from medical records), one of which must have
included treatment with an antidepressant medication, and
the other with either an antidepressant medication or a psy-
chological intervention. Exclusion criteria were: receiving
psychodynamic psychotherapy in the past two years; cur-
rently, or in the past five years, meeting DSM-IV criteria for
psychotic disorder or bipolar I disorder; receiving psychiatric
input for substance dependence in the past two years; mod-
erate or severe learning disability, and evidence of organic
brain disorder. No assessment for presumed suitability or
unsuitability for psychoanalytic forms of therapy was
performed.
Treatments
LTPP consisted of 60 (50 min) sessions of once-weekly
individual psychoanalytic psychotherapy over 18 months.
The treatment manual (28) describes the intervention and
methods, which are based on the view that depression is an
outgrowth of current life difficulties arising out of painful
and continuing ambivalence first felt in relation to those of
the greatest emotional significance to the patient early in
the course of his/her development.
The theory employed in LTPP assumes that, in patients
with treatment-resistant depression, problems with psycho-
social functioning impair help-seeking and illness-combating
behaviors, and may also have an emotional impact upon
health care/service providers in a way that affects the care
they offer (29,30). LTPP enables these patients to gradually
internalize a psychological capacity to relate to pathogenic
personal experiences, memories, feelings, beliefs and rela-
tionships in a reflective, yet also more active, manner (31).
All the therapists (N522; average years of experience:
17.45) had a mental health qualification and a training
approved by the British Psychoanalytic Council. All therapy
sessions were audio-recorded. Fidelity to treatment was
assessed with the 100-item Psychotherapy Process Q-Sort
(32). Three randomly selected sessions from the early, middle
and end phases of each treatment were rated (183 sessions in
total). Inter-rater reliability, assessed in a subsample of 90 ses-
sions, was excellent: intraclass correlation coefficients (ICCs)
after Spearman-Brown correction ranged from 0.68 to 0.98
(mean 0.87). As expected, analysis revealed that in 82.2% of
cases the highest correlation obtained was with the psycho-
dynamic prototype (mean r50.45, p<0.001), with the re-
mainder (17.8%) best resembling the CBT prototype (mean
r50.28, p<0.05).
TAU consisted of interventions as directed by the referring
practitioner. This could include referral for other specialist
provisions. In the UK’s NHS, the range of these interventions
is defined, and to an extent specified, in the treatment guide-
lines of the National Institute for Clinical Excellence (33).
Referral to psychoanalytic psychotherapy is not within the
guidance. In the LTPP group, the short-term forms of psy-
chological therapy included in the guidelines were not
allowed. Treatments received were recorded using the Client
Service Receipt Inventory (34) and health care records.
Assessments
Assessments were based on data collected at entry; at 6,
12 and 18 months over the course of treatment; and at 24,
30 and 42 months during follow-up.
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The primary outcome measure was the HDRS-17, modi-
fied to include increases in sleep, appetite and weight (35).
Trained interviewers blinded to treatment condition con-
ducted the evaluations. All evaluations were recorded, and
all interviews were double-rated by an independent blinded
coder to establish inter-rater reliability. An ICC of 0.89 was
obtained for the total HDRS-17 score with the following
severity bands: 0-7 not depressed, 8-13 mild depression, 14-
18 moderate depression, 19-22 severe depression, 23 very
severe depression. Full remission was defined as an HDRS-
17 score of 8 or less (36). Following Hollon et al (14),
HDRS-17 scores 12 were considered to meet criteria for
partial remission.
Secondary outcomes included self-reported depression as
assessed by BDI-II; social functioning as evaluated by the
Global Assessment of Functioning (GAF, 37); subjective
wellbeing as rated by the Clinical Outcomes in Routine Eval-
uation - Outcome Measure (CORE-OM, 38); and satisfac-
tion with general activities as assessed by the Quality of Life
Enjoyment and Satisfaction Questionnaire (Q-LES-Q, 39).
Statistical analysis
Data analysis was by intention to treat. All analyses
were carried out using Stata Statistical Software Release
14 (40). Power calculations were based on statistical ana-
lysis of data from another trial of long-term psychody-
namic therapy with a similarly heterogeneous population
(41). We conservatively assumed an intra-cluster correla-
tion coefficient for therapists of 0.05: with a minimum of
10 therapists delivering each therapy, each seeing on
average five patients, the study with N5129 has 80%
power to reject the null hypothesis of equivalence, with a
non-infidelity margin equal to an effect size of 0.5 using a
95% one-sided confidence interval, on the basis of a 80%
rate of follow-up to 42 months. Adequacy of randomiza-
tion was assessed by between-group comparisons of base-
line characteristics on all measures, using v2 tests for
dichotomous variables and Kruskal-Wallis statistics and t-
tests for count and interval data.
Treatment differences and changes over time were ana-
lyzed using the STATA ME package, which fits mixed-
effects models (also known as multilevel models and hierar-
chical models) for a variety of distributions of the response
conditional on normally distributed random effects (42).
Mixed-effects models use all available data. The MIXED
procedure was used for the continuous variables, including
HDRS-17, BDI-II and Q-LES-Q scores. MELOGIT was
used for categorical outcomes. With outcome measures that
proved highly positively skewed, multilevel mixed-effects
ordered probit regression (MEOPROBIT) models were
applied. All model parameters for continuous outcome
measures are presented here as partial standardized effects.
Those for the categorical outcome measures are presented
as conditional odds ratios (ORs).
The six time points of assessment were coded as27 (base-
line),26 (6 months),25 (12 months),24 (18 months) of the
review period, and 23 (24 months), 22 (30 months) and 0
(42 months) of the follow-up, in all models where 6-monthly
data were available, thereby implying that regression coeffi-
cients involving time measured the linear rate of change from
baseline to 42-month follow-up, and that regression inter-
cepts referenced group differences at the last follow-up point.
Models with random intercepts were initially fitted. Random
slopes were added when likelihood ratio tests indicated a sig-
nificant improvement of fit. In preliminary models, there was
evidence of strong non-linear change effects in both patient
groups. A quadratic time variable was therefore included in
all models, but was removed if the likelihood ratio test indi-
cated a non-significant improvement in fit.
Categorical outcome measures were best fitted by a logis-
tic proportional odds random intercepts and slopes model.
Continuous outcomes were best represented by a linear ran-
dom intercepts and slopes model. Where data were serious-
ly positively skewed, we fitted multilevel mixed-effects
ordered probit regression models where the actual values
taken on by the dependent variable were irrelevant, except
that larger values were assumed to correspond to “higher”
outcomes. As the LTPP group proved to be significantly bet-
ter educated, despite random assignment to treatment
groups, effects for all outcome measures were adjusted by
additionally incorporating covariates for higher education
into all fitted models. Adjusting for education also con-
trolled for correlated observed asymmetries in employment
and being in receipt of state (welfare) benefits.
Only those primary model parameters directly relevant to
the study’s objectives are presented here. These are: the over-
all significance of the model (Wald v2 statistic); modelled
(intention-to-treat) group differences at 42 months (indicat-
ing whether LTPP plus TAU was better or worse than TAU
alone at the last follow-up time point); the linear rate of
change from baseline to 42 months for both groups com-
bined (indicating the extent to which participants improved
or deteriorated over the 3.5 years of the study); and the dif-
ferential rate of change for the LTPP group (indicating
whether the rate of improvement or deterioration in this
group was substantially greater than in the control group).
RESULTS
Baseline characteristics
The 42 patients who, after interview, declined to partici-
pate did not differ significantly from those who accepted on
any clinical variable.
Table 1 summarizes pre-treatment demographic and clin-
ical characteristics of the 129 patients who were random-
ized to the two treatment conditions. The majority of these
patients scored within the severe range on both HDRS-17
and BDI-II. The reported average of almost four previously
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failed treatment attempts and the average GAF score <50
also highlight the considerable clinical challenge presented
by this severely and chronically depressed patient group.
Patient flow is displayed in Figure 1. Attrition over four
years was relatively low at 25%. Missing values were not a
major problem: across all points, observations were avail-
able for 82% of primary and 75% of secondary outcome var-
iables. There was no difference in the distribution of com-
pleter categories between the treatment groups (v251.87,
df52, p50.18).
The two groups did not differ significantly on any pre-
treatment characteristics, except that patients randomized
to the LTPP group had more tertiary education (p<0.01),
were more often employed (p<0.02), and received fewer
state benefits (p<0.02) (see Table 1). All subsequent analy-
ses statistically controlled for this asymmetry.
Outcomes
Complete remission (HDRS 8) was infrequent in both
groups at the end of treatment (9.4% vs. 6.5%; v250.3;
p50.59; relative risk, RR51.4; 95% CI: 0.3-5.8; number
needed to treat, NNT534) and at 42-month follow-up
(14.9% vs. 4.4%; v252.9; p50.09; RR53.4; 95% CI: 0.7-
15.6; NNT59.6).
As shown in Table 2, partial remission (HDRS 12) was
not significantly more likely in the LTPP than in the control
group at the end of treatment (32.1% vs. 23.9%; v250.8;
p50.37; RR51.3; 95% CI: 0.6-2.5; NNT512.3), but signifi-
cant differences emerged during follow-up (at 24 months:
38.8% vs. 19.2%, v254.5, p50.03, RR52.0, 95% CI: 1.1-4.1,
NNT55.1; at 30 months: 34.7% vs. 12.2%, v256.9,
p50.008, RR52.8, 95% CI: 1.2-6.6, NNT54.5; at 42
months: 30.0% vs. 4.4%, v2510.3, p50.001, RR56.7, 95%
CI: 1.6-28.3, NNT53.9).
The odds of partial remission increased for both groups
during the review period, but was 40% higher per 6-
month period for the LTPP group. The difference be-
tween the estimated odds was significant at 24 months
(D51.1, 95% CI: 0.08-2.1, p50.034); 30 months (D51.5,
95% CI: 0.32-2.5, p50.012); 36 months (D51.8, 95% CI:
0.50-3.1, p50.007) and 42 months (D52.1, 95% CI: 0.64-
3.6, p50.005).
Mean HDRS-17 scores for all time points are displayed
in Table 3. The difference between the group means became
significant only at 24 months. The linear decrease in depres-
sion scores was significantly greater for the LTPP group
(p<0.05). The model yielded a significant difference
between groups at 42 months (p<0.01).
Using a cut-off point of 24 on the BDI-II for partial remis-
sion from moderate or severe depression, significantly more
of the LTPP than the control group were in remission at 42
months (52.4% vs. 20.0%; v259.3; p50.002; RR52.6; 95%
CI: 1.3-5.2; NNT53.2). The mixed-effects model analysis,
which predicted self-reported remission based on all obser-
vations (intention to treat) and included adjustments for
covariates, confirmed the significance of the group differ-
ences at 42 months, and the decrease in the OR was signifi-
cantly steeper for the LTPP group (Table 2). Modelling indi-
vidual BDI-II scores showed the linear rate of decrease to
be somewhat greater for the LTPP group (p<0.05). Again,
Table 1 Pre-treatment demographic and clinical characteristics
of the LTPP and control groups
LTPP group
(N567)
Control
group
(N562)
Age (years, mean6SD) 42.76 10.4 46.16 9.9
Gender (female, %) 66.7 66.1
Currently married or
cohabiting (%)
17.9 17.7
Living alone (%) 82.1 82.3
Tertiary education (%)** 59.7 35.5
Current employment (%)* 52.2 29.0
Receiving state benefits (%)** 41.8 64.5
Duration of depressive illness
(years, mean6SD)
24.46 11.6 19.66 10.8
Duration of current episode
(years, mean6SD)
3.76 3.4 3.86 2.6
Previously failed treatment
attempts (N, mean6SD)
3.56 1.4 3.96 1.8
Previous suicide attempts
(N, mean6SD)
0.96 1.3 0.96 1.3
HDRS-17 score (mean6SD) 19.86 5.1 20.46 4.9
HDRS-17 severe or very
severe depression (%)
53.7 59.6
HDRS-17 moderate
depression (%)
34.3 33.9
HDRS-17 mild depression (%) 11.9 6.5
BDI-II score (mean6SD) 36.56 10.1 36.76 9.5
BDI-II severe depression
(score >29) (%)
74.6 77.4
Any comorbid anxiety disorder (%) 73.1 77.4
Any comorbid substance
use disorder (%)
19.4 17.7
Any comorbid eating disorder (%) 16.4 9.7
Current Axis I diagnoses
(N, mean6SD)
3.56 1.4 3.26 1.4
GAF score (mean6SD) 49.16 7.0 48.86 6.1
GAF <50 (%) 53.7 56.5
CORE global distress
score (mean6SD)
22.86 6.0 22.56 6.1
CORE severe distress
(score >26) (%)
44.5 40.0
LTPP – long-term psychoanalytic psychotherapy, HDRS-17 – 17-item Hamil-
ton Depression Rating Scale, BDI-II – Beck Depression Inventory - II, GAF –
Global Assessment of Functioning, CORE – Clinical Outcomes in Routine
Evaluation
*p<0.02, **p<0.01
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the model yielded a significant difference between groups at
42 months (p<0.05) (Table 3). Graphical representations of
these data are available from the authors upon request.
The number of participants no longer meeting DSM-IV
criteria for major depressive disorder is also shown in Table
2. Mixed-effects logistic regression indicated a significant dif-
ferential change in proportional ORs across the measure-
ment points. By 42 months, 44% of the LTPP group but only
10% of the control group were in remission (v2514.7;
p50.0002; RR54.4; 95% CI: 1.7-10.8; NNT52.9).
Table 4 includes the mean ratings on the GAF scale.
These improved for both groups over the 18-month treat-
ment and the two years of follow-up. Improvement in the
LTPP group was greater, with a highly significant observed
difference at 42 months (t53.3; p50.001; d50.69; 95% CI:
0.26-1.11). Table 4 also shows observed and modelled
improvement for both groups on self-rated subjective well-
being (CORE-OM) and satisfaction with general activities
(Q-LES-Q), but with substantially greater benefits accruing
to the LTPP group.
Treatments received
There were no significant between-group differences in
the total number of prescribed medications, which increased
from an average of just over two to over five in the course of
the treatment; there were no significant reductions in these
figures during the follow-up period (Table 5). As per protocol,
the LTPP group received more psychoanalytic psychothera-
py (average 41 hours, p<0.0001), while the control group
received larger amounts of other types of psychosocial treat-
235 diagnostic interview 
62 allocated to control group
Treatment period (18 months) 
10 drop-outs
8 withdrawn 
2 lost contact 
     7 terminated LTPP early 
         but continued assessments
                 51 completed (76%) 
67 included in ITT analysis 
                 46 completed (74%) 
62 included in ITT analysis 
129 entered into trial 
Treatment period (18 months) 
8 drop-outs 
6 withdrawn 
1 lost contact 
1 deceased
67 allocated to LTPP group
73 ineligible 
44  No response to letter 
12  Funding refused 
  6  Declined to participate 
  3  Non-English speaking 
  5  Moved or lived too far 
  3  Other 
106 not entered into trial
  24 Failed to attend interview 
  39 Screened out at interview 
  27 Depression criteria unsatisfied 
    3 Bipolar disorder 
    3 Psychosis 
    3 Substance dependence 
    3 Psychodynamic treatment 
         in past 2 years 
    1 Imminent suicide risk 
  14 Declined assessments 
    2 Refused recording 
    2 Did not want treatment 
    4 Sought other treatment 
  20 Refused randomization 
308 patients screened for eligibility 
Follow-up period (2 years) 
6 drop-outs 
3 withdrawn 
3 lost contact 
Follow-up period (2 years) 
8 drop-outs 
4 withdrawn 
4 lost contact 
Figure 1 CONSORT diagram of patient flow through the study. LTPP – long-term psychoanalytic psychotherapy, ITT – intention to treat
316 World Psychiatry 14:3 - October 2015
ments (average 11 hours, p<0.002), particularly counseling
(27%) and CBT (19%). Patients of the control group were
also significantly more likely to receive psychiatric/medical
attention (37% vs. 21%).
Over follow-up, the two groups were not significantly dif-
ferent in terms of treatment received, although LTPP partic-
ipants were slightly more likely to have received further psy-
chodynamic psychotherapy outside the trial.
Table 2 Group differences on indicators of depression (categorical measures)
Partial remission (HDRS-17)
Partial remission from
moderate/severe
depression (BDI-II)
Remission of major
depression diagnosis
(SCID)
LTPP group Control group v2 LTPP group Control group v2 LTPP group Control group v2
6 months 12/61 (19.7%) 6/56 (10.7%) 1.8 14/48 (29.2%) 11/39 (28.2%) 0.0 Not collected
12 months 13/56 (23.2%) 11/52 (21.1%) 0.1 21/46 (45.7%) 7/40 (17.5%) 7.7** Not collected
18 months 17/53 (32.1%) 11/46 (23.9%) 0.8 21/45 (46.7%) 11/39 (28.2%) 3.0 20/55 (36.4%) 6/52 (11.5%) 9.0**
24 months 19/49 (38.8%) 9/47 (19.2%) 4.5* 20/41 (48.8%) 10/38 (26.3%) 4.2* 24/53 (45.3%) 8/53 (15.1%) 11.5***
30 months 17/49 (34.7%) 6/49 (12.2%) 6.9** 21/43 (48.8%) 14/41 (34.1%) 1.9 18/51 (35.3%) 7/54 (13.0%) 7.2**
42 months 14/47 (30.0%) 2/45 (4.4%) 10.3*** 22/42 (52.4%) 8/40 (20.0%) 9.3** 22/50 (44.0%) 5/50 (10.0%) 14.7***
Modelled odds ratios (95% CI) Modelled odds ratios (95% CI) Modelled odds ratios (95% CI)
Model: Wald v2(df55) 60.2*** 49.7*** 39.2***
Linear change
(both groups)
4.67*** (2.84, 7.70) 2.71*** (1.80, 4.11) 4.20** (1.51, 11.40)
Quadratic change
(both groups)
0.81*** (0.76, 0.86) 0.88*** (0.83, 0.93) 0.79*** (0.70, 0.88)
Differential linear
change (LTPP)
1.41* (1.05, 1.89) 1.33* (1.05, 1.68) 2.37* (1.18, 4.84)
Group differences
at 42 months
0.09* (0.01, 0.16) 0.13* (0.01, 0.24) 0.22*** (0.09, 0.36)
LTPP – long-term psychoanalytic psychotherapy, HDRS-17 – 17-item Hamilton Depression Rating Scale, BDI-II – Beck Depression Inventory - II, SCID –
Structured Clinical Interview for DSM-IV
*p<0.05, **p<0.01, ***p<0.001
Table 3 Group differences on indicators of depression (continuous measures)
HDRS-17 scores (mean6SD) BDI-II scores (mean6SD)
LTPP group Control group t LTPP group Control group t
Baseline (N5129) 19.865.1 20.264.8 0.6 36.5610.1 36.769.5 0.2
6 months (N5117) 16.866.0 18.365.8 1.4 29.9612.4 32.6615.3 0.9
12 months (N5108) 17.166.1 17.966.3 0.6 27.4614.5 34.7613.4 2.4**
18 months (N599) 16.466.2 17.966.5 1.1 28.0612.8 34.3616.6 2.1*
24 months (N596) 15.466.6 17.666.1 1.7* 25.9616.4 34.1616.1 2.3**
30 months (N598) 16.767.4 19.466.5 1.9* 27.0616.0 31.0615.8 1.3
42 months (N592) 15.966.8 20.165.4 3.2*** 24.0614.4 34.5614.2 3.3***
Adjusted model coefficients (95% CI) Adjusted model coefficients (95% CI)
Model: Wald v2(df55) 53.3*** 44.4***
Linear change (both groups) 21.20*** (21.64, 20.74) 22.22*** (23.26, 21.17)
Quadratic change (both groups) 0.17*** (0.11, 0.22) 0.28*** (0.14, 0.42)
Differential linear change (LTPP) 20.36** (20.64, 20.07) 20.84* (21.57, 20.12)
Group differences at 42 months 22.71** (25.16, 20.29) 26.94* (212.87, 21.00)
LTPP – long-term psychoanalytic psychotherapy, HDRS-17 – 17-item Hamilton Depression Rating Scale, BDI-II – Beck Depression Inventory-II
*p<0.05, **p<0.01, ***p<0.001
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DISCUSSION
This is the first fully randomized controlled trial of a man-
ualized LTPP for treatment-resistant depression. Improve-
ments in depression were modest but comparable between
the LTPP and the control group until termination of treat-
ment, while differences emerged from 24 months post-
randomization, with the LTPP group mostly maintaining
the gains achieved while the control group appeared to be at
greater risk of relapse. At 2-year follow-up, almost one-third
of the participants receiving LTPP were still in partial remis-
sion, compared with only 4% of those in the control group.
At that time, 44% of the LTPP group no longer met diagnos-
tic criteria for major depressive disorder, compared with
10% of those receiving TAU alone.
The effect sizes observed are in the medium range. The
long-term outcomes of LTPP compare favorably with effect
sizes reported in comprehensive reviews (3), including
those used by the UK treatment recommendations (33).
Studies that show stronger effects tend to observe patients
in whom treatment resistance is less evident and lack infor-
mation about long-term outcomes (43). Further compari-
sons, including longer manualized treatments based upon
other (non-psychoanalytic) psychological therapy modali-
ties such as CBT, are needed to establish the specificity of
the therapeutic gain reported here.
As predicted, differences between the LTPP and the con-
trol group increased during follow-up on most measures. A
Finnish longitudinal study of LTPP has reported a similar
pattern with a less chronically depressed patient group (44),
suggesting that LTPP may require some time post-treatment
for its full effects to become evident (45). End-of-treatment
evaluations or follow-ups that are too short may miss the
emergence of this delayed therapeutic benefit.
While this study has ecological validity in that it employed
a relatively unselected sample and incorporated a compara-
tively long follow-up, it has several limitations. First, the
design of the study did not allow masking of patients to the
treatment allocation, which may have generated an expecta-
tion bias. Second, although mixed-effects models are thought
to be robust even to selective loss of data (46), we still failed
to collect primary outcome data for over 25% of patients at
42 months, despite an unusually good level of retention for
patients with depression of this severity. Third, the differ-
ences between the effects associated with the two treatments
could have arisen as a result of the disparities between their
respective numbers of contact hours, intensity, and quality of
case management (47). Fourth, in spite of robust procedures,
randomization yielded a difference between groups in educa-
tion level, with associated asymmetries in employment and
state benefits, which we were forced to adjust for statistical-
ly. Reanalysis in which the samples were balanced by selec-
tively excluding patients did not alter the basic pattern of
findings. Fifth, while we were concerned to measure
outcome over an extended period, we omitted to include an
interval depression measure such as the Longitudinal
Interval Follow-up Evaluation (48). Sixth, since the study
was planned and conducted by the developers of the inter-
Table 4 Group differences in measures of social functioning, subjective wellbeing and satisfaction with general activities
GAF scores
(mean6SD)
Subjective wellbeing,
CORE-OM (mean6SD)
Satisfaction with general
activities, Q-LES-SQ (mean6SD)
LTPP group
Control
group t LTPP group
Control
group t LTPP group
Control
group t
Baseline (N5129) 49.167.1 48.866.1 0.2 2.460.6 2.360.6 0.8 28.9614.7 29.2615.1 0.1
6 months (N5115) Not collected 2.260.7 2.260.8 0.2 36.3615.8 35.3617.5 0.3
12 months (N5106) Not collected 2.260.7 2.360.7 0.7 37.1615.2 35.2616.8 0.6
18 months (N596) 57.369.8 52.569.2 2.4** 2.060.7 2.360.8 1.8* 38.8618.0 32.6619.9 1.5
24 months (N594) 60.169.7 54.369.2 3.0** 1.960.8 2.260.8 1.6* 43.1621.2 30.9621.0 2.5**
30 months (N595) 58.6612.5 52.6611.9 2.4** 1.960.8 2.160.9 0.7 41.7620.1 35.3622.0 1.4
42 months (N591) 60.0612.9 52.468.1 3.3*** 1.860.8 2.360.7 2.9** 45.6619.9 32.0619.0 3.1***
Adjusted model coefficients (95% CI) Adjusted model coefficients (95% CI) Adjusted model coefficients (95% CI)
Model: Wald v2(df55) 98.0*** 29.3*** 40.1***
Linear change (both groups) 2.29*** (1.53, 3.05) 20.08** (20.14, 20.02) 2.12** (0.62, 3.62)
Quadratic change (both groups) 20.25*** (20.34,20.15) 0.01** (0.00, 0.02) 20.29** (20.48,20.10)
Differential linear change (LTPP) 0.81** (0.24, 1.38) 20.06** (20.10,20.01) 1.75*** (0.67, 2.82)
Group differences at 42 months 6.01** (1.80, 10.22) 20.32* (20.64, 20.00) 10.33** (2.46, 18.21)
LTPP2 long-term psychoanalytic psychotherapy, GAF2Global Assessment of Functioning, CORE-OM2Clinical Outcomes in Routine Evaluation - Outcome
Measure, Q-LES-SQ2Quality of Life Enjoyment and Satisfaction Questionnaire
*p<0.05, **p<0.01, ***p<0.001
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vention, there is a risk of allegiance bias (49). We tried to
minimize this risk by having the primary outcome measure
assessments made by interviewers who were blinded to the
treatment condition. Seventh, these results were delivered
by a single provider organization. This may limit generaliz-
ability. However, a multi-center German trial (the LAC
Study) (50), testing LTPP using the same manual with a sim-
ilar patient group, will shortly report.
In conclusion, while the benefit of both interventions for
this severely affected group of patients with major depres-
sive disorder was limited, a moderate difference emerged
over long-term follow-up in favor of the LTPP condition.
Further studies are needed to replicate this finding, ascer-
tain its clinical utility, understand the mechanisms involved,
and identify factors associated with response or non-
response to treatment.
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